Mirum Pharmaceuticals, Inc. (MIRM) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

MIRM — Fair Value Analysis

Mirum Pharmaceuticals, Inc.

Current: $99.83Overvalued

Fair Value Range

Bear Case (25th pct.)

$4.15

-95.8% vs price

Base Case (Median)

$4.87

-95.1% vs price

Bull Case (75th pct.)

$5.60

-94.4% vs price

$4.15$4.87$5.60

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$6.32	-93.7%	High (40%)
EV/EBITDA	$3.43	-96.6%	Medium (20%)

Interpretation

Based on 2 out of 8 methods, MIRM appears overvalued at the current price of $99.83. The base case fair value of $4.87 implies 95.1% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.